Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2009 June;48(2) > Minerva Pneumologica 2009 June;48(2):165-75





A Journal on Diseases of the Respiratory System

Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index




Minerva Pneumologica 2009 June;48(2):165-75

language: English

Cytomegalovirus infections in lung transplantation

Solidoro P. 1, Libertucci D. 1, Bardessono M. 1, Braida A. 1, Ruffini E. 2, Costa C. 3

1 Operative Unit of Pneumology University Hospital S. Giovanni Battista Turin, Italy
2 Operative Unit of Thoracic Surgery University Hospital S. Giovanni Battista Turin, Italy
3 Operative Unit of Virology University Hospital S. Giovanni Battista Turin, Italy


Among solid organ recipients lung transplantation recipients are at highest risk to be affected by cytomegalovirus infection (CMV) or to die from CMV disease. Furthermore acute and chronic lung rejection represents the most serious complication limiting long term survival for these patients. Despite advances in surgical techniques and immunosuppressive therapy to prevent allograft rejection, the clinical importance of CMV has grown in parallel with the increasing number of solid organ transplant recipients. The clinical symptoms related to CMV disease and the prevention of CMV infection show variation among different patient populations, depending on the type of transplant and the intensity of immunosuppression. In particular, in lung transplantation, CMV infection seems to be related to acute and chronic rejection leading to a self-manteining prone to the graft disfunction. Treatment and prevention of CMV infection have assumed increasing importance in care of transplant recipients relative to the availibility of effective antiviral agents as well as new diagnostic techniques and the prophylaxis, diagnosis, and treatment of CMV infections in lung transplant recipients is evolving with experience. Due to the high mortality rate associated with CMV disease in the transplantation setting, the optimal management strategy for the control of CMV infection is the prevention of overt disease. The two main approaches for prevention of CMV disease are antiviral prophylaxis and preemptive therapy using the currently available anti-CMV compounds. An overview of CMV infection following lung transplantation will be presented here.

top of page

Publication History

Cite this article as

Corresponding author e-mail